Needham Maintains Their Hold Rating on Cardiovascular Systems (CSII)

In a report released yesterday, Michael Matson from Needham maintained a Hold rating on Cardiovascular Systems (CSIIResearch Report). The company’s shares closed yesterday at $44.85.

According to TipRanks.com, Matson is a 5-star analyst with an average return of 7.8% and a 63.7% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Merit Medical Systems.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cardiovascular Systems with a $52.33 average price target.

See today’s analyst top recommended stocks >>

Cardiovascular Systems’ market cap is currently $1.56B and has a P/E ratio of 780. The company has a Price to Book ratio of 11.03.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications.